Trial Profile
Phase I Study of Regorafenib and Sildenafil for Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Regorafenib (Primary) ; Sildenafil (Primary)
- Indications Cervical cancer; Gynaecological cancer; Ovarian cancer; Solid tumours
- Focus Adverse reactions
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology.
- 11 May 2020 According to a Bayer media release, data from this trial will be presented at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program on Friday, May 29, and will be available on the ASCO website
- 19 Feb 2020 Status changed from active, no longer recruiting to completed.